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PNTRODUCTION
schemic Heart Disease in Women
arl J. Pepine, MD
ainesville, Florida
This supplement is intended to provide a specialized forum to overview new information on
the pathophysiology, diagnosis, and outcomes of women with suspected ischemic heart
disease (IHD). Led by Women’s Ischemic Syndrome Evaluation (WISE) study investigators
and other experts, the scientific summaries contained in this supplement will permit sharing
of current knowledge about this important clinical problem. Improved understanding in these
areas will advance the prevention and treatment of IHD in women. These comments by the
investigators and experts, as well as those from a recent National Heart, Lung, and Blood
Institute consensus conference, should also provide direction for future studies in this critical
area. (J Am Coll Cardiol 2006;47:1S–3S) © 2006 by the American College of Cardiology
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.10.022Foundation
a
f
C
I
r
s
v
b
d
r
W
D
W
g
g
c
s
c
m
fi
m
p
o
g
l
t
a
i
i
d
a
e
i
dhis Journal of the American College of Cardiology supple-
ent is developed to share new information on the problem
f ischemic heart disease (IHD) in women, a topic that has
eceived inadequate attention (1). The new data are a result
f an initiative by the National Heart, Lung, and Blood
nstitute (NHLBI). The NHLBI, through sponsorship of
he Women’s Ischemic Syndrome Evaluation (WISE)
tudy, created the opportunity to investigate some of the
eficiencies in our knowledge base about the clinical aspects
f this critically important problem. Specifically, these
tudies were directed to focus on diagnostic testing and
athophysiology of IHD in women and how sex hormones
nd other gender-specific findings influence the clinical
spects of this disease (2). The overall design was a
rospective cohort recruited at four sites with expertise in all
spects of IHD. The general approach was to screen women
eferred for diagnostic coronary angiography to further
valuate signs and symptoms suggesting IHD. Data were
ollected on conditions present at entry, and standard as
ell as novel tests were then applied. Entry data and test
ndings were examined for links with the presence and
everity of coronary artery obstruction, assessed qualitatively
nd quantitatively by a core laboratory. The project was
ivided into a one-year pilot phase (256 women) and a
hree-year full study phase (680 additional women) to
rospectively evaluate test findings. The initial results fo-
used on diagnosis and pathophysiological mechanisms.
he later results evaluate the relationship of test findings
ith adverse outcomes in all 936 participants. The project
From the Division of Cardiovascular Medicine, University of Florida College of
edicine, Gainesville, Florida. Supported by NHLBI contracts NO1-HV-68161,
O1-HV-68162, NO1-HV-68163, and NO1-HV-68164, and grants UO1-
L64829-01, UO1-HL64914-01, and UO1-HL65924-01; GCRC grant MO1-
R00425 from the National Center for Research Resources; and grants from the
ustavus and Louis Pfeiffer Research Foundation, Denville, New Jersey, and the
adies Hospital Aid Society of Western Pennsylvania, Pittsburgh, Pennsylvania.i
Manuscript received August 24, 2005; revised manuscript received September 13,
005; accepted October 11, 2005.lso has a number of substudies, and ancillary studies
ocused on specific areas of interest.
ONTRIBUTIONS FROM THE WISE STUDY
n this unique supplement, we have assembled pertinent
esults from the WISE clinical scientists and also included
ubject matter experts and opinion leaders to provide over-
iews on selected aspects of IHD in women. These contri-
utions have shaped, and will continue to shape, the many
iagnostic and therapeutic facets of this challenging area.
The supplement begins with a cluster of articles summa-
izing the results of this ongoing effort in three parts by
ISE investigators. In Part I of the “Ischemic Heart
isease in Women: Insights From the NHLBI-Sponsored
ISE Study,” Shaw et al. (3) review findings dealing with
ender differences in risk factors, symptom evaluation, and
ender-specific optimized diagnostic strategies. They con-
lude that variability in onset and risks, along with the
ynergy of traditional and novel risk conditions in women,
reates a challenge for clinicians leading to suboptimal
anagement. They emphasize that some unique risk pro-
les in women, like hypoestrogenemia and protracted dys-
etabolic state, may promote an inflammatory milieu that
rovokes symptoms and ischemia without obstructive cor-
nary artery disease (CAD). Further, they suggest that, in a
rowing portion of such women, symptoms and functional
imitations may relate to metabolic alterations. Thus, tests
o detect obstructive CAD (e.g., stress echocardiography
nd stress single-photon emission computed tomographic
maging) are better utilized to guide decision making by
dentifying women at risk.
In Part II, Bairey Merz et al. (4) review how vascular
isease may affect gender-specific differences in metabolic
lterations, vascular wall findings, plaque deposition, and
xpression of adverse outcomes. They conclude that new
nvestigative strategies encompassing symptoms, functional
isability, diminished quality of life, risk factors, and new
maging techniques for vascular dysfunction need to be
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Introduction: IHD in Women February 7, 2006:1S–3Seveloped to improve IHD risk assessments and interven-
ions for women.
The third article provides an overview of the coronary
ascular findings underlying IHD in women (5). This
ncludes a summary of some risk conditions unique to
omen that, in addition to traditional risk factors, may
romote IHD. This article concludes with a first description
f a female-specific vasculopathy that is characterized by a
revalent underlying non-endothelial-dependent microvas-
ular dysfunction superimposed upon endothelial dysfunc-
ion. These features contribute to a very defuse involvement
y the disease process throughout the entire coronary
ascular tree of many postmenopausal women.
EW FINDINGS FROM THE WISE STUDY
he next cluster of articles deals with specific new findings
rom the WISE. These begin with a report on the value of
stimated functional capacity in predicting outcome (6).
haw et al. (6) conclude that estimated functional capacity
erived from the Duke Activity Status Index (DASI), a
2-question self report, provides valid information predic-
ive of adverse cardiovascular outcomes in these women.
erhaps this instrument, if validated in other female popu-
ations, should be administered in the office as a part of our
iagnostic evaluation.
Also, the estimated functional capacity from the DASI
ppears to be linked to impaired coronary vascular reactivity
o adenosine as detailed in the following manuscript by
andberg et al. (7). From these results, they conclude that
oronary flow reserve may be decreased in response to
edentary lifestyle in these women. Alternatively, the sed-
ntary lifestyle could result from activity limitations caused
y an inadequate vasodilator response.
Next, Gierach et al. (8) present new data on hypertension,
enopause, and CAD risk from detailed analyses of women
n the WISE study. They conclude that identification of
levated systolic blood pressure and/or pulse pressure de-
nes a subgroup of symptomatic premenopausal women
hat could potentially benefit from additional risk assess-
ent and more intense management.
MPLICATIONS FROM THE
ISE STUDY AND OTHER STUDIES
he last cluster of articles deals with implications from the
esults reported from the WISE and other studies. Lerman
nd Sopko (9) provide viewpoints on clinical evaluation,
Abbreviations and Acronyms
CAD  coronary artery disease
DASI  Duke Activity Status Index
IHD  ischemic heart disease
NHLBI  National Heart, Lung, and Blood Institute
WISE  Women’s Ischemic Syndrome Evaluationon-invasive functional tests, and coronary angiography wndings in women with suspected IHD. They conclude that
bout one-half of the women referred to a cardiology
ractice for suspected ischemia do not have obstructive
oronary disease, yet their prognosis is not benign in terms
f future events and persistent symptoms. They advocate
ore aggressive therapy including statins, angiotensin-
onverting enzyme inhibitors, and aspirin, but they empha-
ize need for randomized trials to assess the utility, as well
s risks and benefits, of this approach. Next, Alice Jacobs
10) provides her perspective on “Revascularization and the
ender Gap: What Are We Missing?” From her long
areer as an interventional cardiologist, she discusses the
urrent status of revascularization in women with acute
oronary syndromes and cardiogenic shock, as well as the
oor outcomes observed in young women. She concludes
ith suggestions about how the pathophysiology findings
hat the WISE investigators have delineated may help to
xplain some of the well recognized gender differences in
HD. Finally, Arshed Quyyumi (11) provides views on the
Pathophysiological Implications From the WISE Study
nd Future Research Steps.” His topics include ischemia
nd microvascular dysfunction, risk factors and vascular
isease, oxidative stress, endothelial function, inflammation,
besity, insulin resistance and metabolic syndrome, ethnic-
ty and genetics. He concludes with the suggestion that
efective repair of continuing vascular injury from an
xhausted or senescent progenitor cell pool may be a central
aradigm defining vascular disease among women at risk.
UMMARY
schemic heart disease in women represents as an important
roblem that is difficult to identify early owing to our
ncomplete understanding of early stage symptoms and
echanisms. A heightened awareness of women at risk of
HD and a different approach than that used in men is
ecessary to allow for diagnosis before late stages develop.
y then, significant pathophysiological changes in the
oronary vasculature may result in sudden death, myocardial
nfarction, congestive heart failure, or need for revascular-
zation. As with most, if not all vascular disease, inflamma-
ion and endothelial dysfunction are key elements of the
athophysiology, and both processes are linked with adverse
utcomes. But women also are likely to have non-
ndothelial-dependent microvascular dysfunction, particu-
arly in the early stages of IHD. Limitations to the prevail-
ng diagnostic evaluation of women are now more clearly
efined. With more data from the WISE, as well as new
tudies, consensus needs to be reached on an algorithm of
iagnostic testing to better assure an accurate early diagnosis
f IHD. Improved understanding of this earlier phase of
isease should lead to innovative management approaches
o prevent or limit the morbid consequences of IHD in
omen.
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